Clinical Trials Using Urelumab

Clinical trials are research studies that involve people. The clinical trials on this list are studying Urelumab. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-4 of 4
  • Anti-LAG-3 Monoclonal Antibody BMS-986016 or Urelumab Alone and in Combination with Nivolumab in Treating Patients with Recurrent Glioblastoma

    This phase I trial studies the safety and best dose of anti-lymphocyte activation gene-3 (LAG-3) monoclonal antibody BMS-986016 or urelumab alone and in combination with nivolumab in treating patients with glioblastoma that has returned (recurrent). Monoclonal antibodies, such as anti-LAG-3 monoclonal antibody BMS-986016, urelumab, and nivolumab may interfere with the ability of tumor cells to grow and spread.
    Location: 13 locations

  • Stereotactic Body Radiation Therapy, Nivolumab, and Urelumab or Cabiralizumab in Treating Participants with Metastases in Advanced Solid Tumors

    This phase I trial studies the side effects and best dose of stereotactic body radiation therapy when given together with nivolumab and urelumab or cabiralizumab in treating participants with solid tumors that have spread to other places in the body. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as nivolumab, urelumab, and cabiralizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving stereotactic body radiation therapy, nivolumab, and urelumab or cabiralizumab may work better in treating advanced solid tumors.
    Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois

  • Nivolumab with or without Urelumab before Surgery in Treating Participants with Muscle-Invasive Bladder Urothelial Cancer

    This randomized phase II trial studies how well nivolumab with or without urelumab before surgery works in treating participants with bladder urothelial cancer that has spread into the muscle tissue. Monoclonal antibodies, such as nivolumab and urelumab, may interfere with the ability of tumor cells to grow and spread. Giving nivolumab and urelumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
    Location: 5 locations

  • Vaccine Therapy with or without Nivolumab or Urelumab before and after Surgery in Treating Patients with Stage I-IIB Pancreatic Cancer That Can Be Removed by Surgery

    This randomized phase I / II trial studies how well vaccine therapy with or without nivolumab or urelumab before and after surgery works in treating patients with stage I-IIB pancreatic cancer that can be removed by surgery. Vaccines, such as GVAX pancreatic cancer vaccine, made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. Monoclonal antibodies, such as nivolumab and urelumab, may block tumor growth in different ways by targeting certain cells. Giving vaccine therapy with or without nivolumab or urelumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving vaccine therapy with or without nivolumab or urelumab after surgery may kill any remaining tumor cells. It is not yet known if vaccine therapy is more effective with or without nivolumab or urelumab before and after surgery in treating patients with pancreatic cancer.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland